Identification of potent and selective TACE inhibitors via the S1 pocket.

By focusing on the P1 portion of the piperidine beta-sulfone ligands we identified a motif that induces selectivity and resulted in a series of TACE inhibitors that demonstrated excellent in vitro potency against isolated TACE enzyme and excellent selectivity over MMPs 1, 2, 9, 13, and 14.

[1]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[2]  J. Skotnicki,et al.  Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates. , 2005, Bioorganic & medicinal chemistry letters.

[3]  R. Black,et al.  Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis , 2004, Journal of Pharmacology and Experimental Therapeutics.

[4]  W A Buurman,et al.  Tumor necrosis factor: function, release and clearance. , 1996, Critical reviews in immunology.

[5]  V. Lukacova,et al.  A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. , 2005, Journal of medicinal chemistry.

[6]  J. Levin.  The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. , 2004, Current topics in medicinal chemistry.

[7]  David J Nelson,et al.  Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling. , 2003, Chemistry & biology.

[8]  Colin McMartin,et al.  QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..

[9]  R. Powers,et al.  The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors. , 2004, Current topics in medicinal chemistry.

[10]  B. Aggarwal,et al.  Tumor necrosis factors: developments during the last decade. , 1996, European cytokine network.

[11]  Kentaro Kawai,et al.  Reverse hydroxamate-based selective TACE inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[12]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[13]  R. Black,et al.  Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates. , 2003, Bioorganic & medicinal chemistry letters.

[14]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[15]  F. Lovering,et al.  Therapeutic potential of TACE inhibitors in stroke. , 2005, Current drug targets. CNS and neurological disorders.

[16]  Jeremy Levin,et al.  Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[17]  Bryan W King,et al.  Conversion of potent MMP inhibitors into selective TACE inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[18]  R. Powers,et al.  Impact of mobility on structure-based drug design for the MMPs. , 2002, Journal of the American Chemical Society.

[19]  C. Carron,et al.  Synthesis and Structure−Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy , 2005 .

[20]  Chen Lihua,et al.  Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity Relationships , 2002 .

[21]  Xiaohua He,et al.  Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification. , 2003, Bioorganic & medicinal chemistry letters.

[22]  J. Levin,et al.  Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[23]  J. Trzăskos,et al.  Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors , 2004 .